Duke Eye Center

Changing demographics and increasing trial complexity present challenges and opportunities.

The procedure offers a renewed approach to suprachoroidal drainage, with potential for both combined and standalone glaucoma surgery.

GATHER2 met its prespecified primary endpoint of mean rate of growth (slope) in GA area at 12 months with statistical significance and a favorable safety profile. With this data in hand, Iveric Bio is working to submit a New Drug Application for Zimura to the FDA by the end of the first quarter of next year.

With clearer imaging and enhanced resolution, the new OCT approach could improve medical diagnostic imaging.